Phase II Open-label Trial of Neoadjuvant Immunochemotherapy for Resectable Non-metastatic Colon cancER: NICER

Phase II Open-label Trial of Neoadjuvant Immunochemotherapy for Resectable Non-metastatic Colon cancER: NICER is a phase 2, interventional study registered as NCT05870800 by Baylor College of Medicine, with a registry enrolment figure of 28 participants, started 2025-06-15 and due to reach its primary completion in 2026-09-01. Interventions recorded: Tecentriq 1200 MG in 20 ML Injection + Capecitabine 1000 mg/m2 + Oxaliplatin 130 mg/m2; Oxaliplatin injection 85mg/m2 + Leucovorin 400mg/m2 + 5-Fluorouracil 2400mg/m2; Oxaliplatin 130mg/m2 + Capecitabine 1000mg/m2. Conditions listed: Stage I Colon Cancer; Stage II Colon Cancer; Stage III Colon Cancer. Primary outcome: Determine the rate of tumor regression grade 1 (<10% viable cancer cells) to neoadjuvant immunotherapy and chemotherapy in resectable (non-metastatic) pMMR colon cancer, assessed in the resection specimen.. Colorectal eligibility wording from the registry: "* Histologically or cytologically confirmed resectable non-metastatic adenocarcinoma of the colon". Sites: United States. No results are recorded here; the registry entry is the source.